PRIOR AUTHORIZATION REQUEST FORM
Faricimab-Svoa (Vabysmo®) / Neovascular (wet) age-related macular degeneration (AMD)

DECLARATION OF THE INSURED PERSON

Section 1: Information about the plan member and the patient			
Name of plan member	Insurance policy / certificate	Name of employer	
Name of patient	Date of birth (YYYY/MM/DD)	Telephone	
Address (house number and street name)	City/Town	Province	Postal code

Section 2: Other prescription drug insurance policies			
Do you have other prescription drug insurance?		❒ Yes	❒ No
If so, please answer the following:			
What type of plan is it?		❒ Private	❒ Public
Have you ever submitted a claim for this drug to the other insurer?		❒ Yes	❒ No
What is the status of the claim?	❒ Accepted	❒ Refused	❒ Under review
Did this insurer ask you to complete a prior authorization request?		❒ Yes	❒ No
If so, what is the status of the prior authorization request?	❒ Accepted	❒ Refused	❒ Under review

Please enclose acceptance or refusal documents, if applicable

Section 3: Authorization to disclose personal information

I certify that the information in this prior authorization request is complete, accurate and true.

I authorize physicians and other health care professionals, medical, paramedical, or clinical institutions, care coordinators, members of SSQ's Preferred Pharmacy Network (outside Quebec only) and any public or parapublic organization, including Régie de l 'assurance maladie du Québec, to disclose to SSQ, Life Insurance Company Inc. (SSQ) any of my relevant personal information including and without limitation, any medical information, and medical evaluations in connection with the processing of this request. I hereby waive their confidentiality obligation and authorize them to disclose the requested information to SSQ. In addition, I authorize SSQ to disclose to the previously named third parties any of my relevant personal information including and without limitation any medical information and medical evaluations in connection with the processing of this request.

Photocopies of this document have the same value as the original.

Signature of **patient** (parent/legal guardian) _____ Date _____

IMPORTANT :

All correspondence concerning this form will be sent to the address indicated in the plan member's file.

Send us this duly completed form by mail or by fax to 1-855-453-3942.

Telephone: 418-651-2588/1-800-380-2588 – Fax: 1-855-453-3942 Address: 2525 Laurier Blvd, P.O. Box 10500, Quebec City, QC G1V 4H6

PRIOR AUTHORIZATION REQUEST FORM
Faricimab-Svoa (Vabysmo®) / Neovascular (wet) age-related macular degeneration (AMD)

DECLARATION OF THE PRESCRIBER

Section 4: Information about the prescriber		
Name of prescriber	Specialty	Licence No.:
Telephone	Fax	
I hereby certify that the information in this request is complete, true, and accurate: Signature of **prescriber** _____ Date _____		

Section 5 : Drug covered by the authorization			
Name of drug **Vabysmo**	Pharmaceutical form	Strength	**Dosage** Dose: _____ Frequency of administration: _____

IMPORTANT:
Please do not provide any genetic test results

Section 6 : Clinical information (first request)	
Therapeutic indication ❒ Neovascular (wet) age-related macular degeneration (AMD) ❒ Other. Specify: _____	
Left eye	**Right eye**
Administration of requested prescription drug	
❒ Monotherapy ❒ In conjunction with Specify agent: _____	❒ Monotherapy ❒ In conjunction with Specify agent: _____
Linear dimension of the lesion	
❒ ≤ 12 disc surfaces ❒ Other. Specify: _____	❒ ≤ 12 disc surfaces ❒ Other. Specify: _____

State of the centre of the macula	
❒ No significant permanent structural damage*	❒ No significant permanent structural damage*
❒ Other. Specify: _____	❒ Other. Specify: _____
*The damage is defined as fibrosis, atrophy or chronic disciform scarring, the seriousness of which prevents obtaining a functional benefit according to the attending physician.	
Evolution of the illness over the past 3 months, confirmed by:	
❒ Retinal angiography	❒ Retinal angiography
❒ Optical coherence tomography	❒ Optical coherence tomography
❒ Recent visual acuity change	❒ Recent visual acuity change
❒ Other. Specify: _____	❒ Other. Specify: _____

Section 7 : Additional information